Primary IgAN
Conditions
Brief summary
This is a multicenter, open-label study to evaluate the long-term safety and efficacy of FXS6837 capsules in primary IgAN patients. About 60 IgAN patients who had received and completed FXS6837-IIb-201 study treatment will be enrolled to take FXS6837 capsules orally according to protocol for 2 years.
Interventions
DRUGFXS6837 Capsule
FXS6837 capsule orally taken according to protocol for 2 years
Sponsors
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Have completed the study treatment in FXS6837-IIb-201, and are evaluated by the investigator to have an anticipated benefit exceeding risk with long-term FXS6837 treatment; 2. eGFR (CKD-EPI) ≥ 30 mL/min/1.73 m2 at screening; 3. Vaccinated against Neisseria meningitidis and Streptococcus pneumoniae as required by the previous study (Booster vaccination should be administered promptly in accordance with vaccination guidelines and local immunization authority requirements if the vaccine protection period fails to cover the treatment duration of this study); 4. Able to continue optimized treatment with RASi, SGLT2i, ERA, and hydroxychloroquine throughout the study with stable prescribed dosing; 5. Have a detailed understanding of the nature, significance, possible benefits, potential inconveniences, and potential risks of the trial, and voluntarily participate in this clinical trial; Able to communicate well with the investigators and comply with the requirements of the entire study; And signed a written ICF; 6. Participants of reproductive potential commit to having no plans for pregnancy or sperm/egg donation from screening until 1 month (female participants) or 3 months (male participants) after the last dose and voluntarily take effective physical contraceptive methods (including partners).
Exclusion criteria
1. Known or suspected by investigators to have immunodeficiency diseases or hereditary complement deficiency; 2. Any organ transplant recipients (except corneal transplant); 3. Concomitant major systemic diseases, including but not limited to: advanced heart disease (such as NYHA class IV), severe pulmonary disease (such as severe pulmonary hypertension \[WHO class IV\]), active hepatitis, or other major systemic diseases assessed by investigators as unable to participate in this study; 4. History of malignant tumors within 5 years before screening (except carcinoma in situ and thyroid cancer assessed by investigators as curatively resected). 5\. Previous history of Neisseria meningitidis or recurrent Streptococcus pneumoniae infection ; 6. Suspected or known history of allergies to similar ingredients of the study drug or any ingredient in the study drug; 7. Pregnant or lactating women or those with positive pregnancy test results; 8. Other conditions deemed by the investigator that may potentially interfere with study conduct, impose additional risks to the participant, or render the individual ineligible for study participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and severity of adverse events | through study completion, an average of 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Ratio of urine protein-to-creatinine ratio (UPCR) to baseline at each visit | through study completion, an average of 2 years |
| Ratio of urine albumin-to-creatinine ratio (UACR) to baseline at each visit | through study completion, an average of 2 years |
| Ratio of 24-h urine protein (24 hour-UPE) to baseline at each visit | through study completion, an average of 2 years |
| Ratio of 24-h urine albumin excretion (24 hour-UAE) to baseline at each visit | through study completion, an average of 2 years |
| Change from baseline in estimated glomerular filtration rate (eGFR) at each visit | through study completion, an average of 2 years |
| Trough plasma concentration of FXS6837 | through study completion, an average of 2 years |
| Complement AP activity in peripheral blood at each visit point | through study completion, an average of 2 years |
| Levels and changes of PD biomarkers in plasma and urine at each visit | through study completion, an average of 2 years |
Countries
China
Contacts
CONTACTJicheng Prof. Lv, Doctor
CONTACTYang Dr. Li, Doctor
PRINCIPAL_INVESTIGATORJicheng Lv, Doctor
Peking University First Hospital
Outcome results
None listed